Minder Health Management Study
Research type
Research Study
Full title
Minder Health Management Study
IRAS ID
257561
Contact name
Jessica True
Contact email
Sponsor organisation
Surrey and Border's Partnership NHS Foundation Trust, Research and Development department
ISRCTN Number
ISRCTN71000991
Duration of Study in the UK
6 years, 10 months, 31 days
Research summary
Dementia is a serious disorder, with over 850,000 affected in the UK, costing £23bn annually.
The aim of our Technology for Integrated Health Management (TIHM 1.0) for dementia randomised control trial (RCT) was to improve quality of life for people with dementia and their carers and keep people well at home for longer.
Our research study explored the use of IoT technologies where we gathered a combination of environmental, behavioural and biological data from a range of passive sensors, environmental monitoring/smart metering and CE approved vital body monitoring signs deployed into the homes of people with dementia who were consented into the trial alongside their carers.
We have been funded for a second phase development - TIHM 1.5, to refine and evaluate the intervention in order to commercialise the offer and scale.
We have further secured funding for 6 years from Dementia Research Institute.
We have also secured funding for 6 months for COVID-19 arm of the study.This extension of the study is to change the status of the study to a clinical investigation of a non-CE marked medical device in view of our commercialisation intent.
This refinement phase (TIHM 1.5) will adopt a single-arm (intervention only) - with Trusted User group, mixed method, adaptive design (action research).
The study focuses on:
-Refining the use of combinatorial approach based on efficacy, cost, usability, acceptability with a view to spread
-Supporting people at home for longer and reduce carer burden through prediction of declining health status and early interventions
-Gathering longitudinal outcome data using agile research methodology to supp
The expectation from our funders is that we should have a product that we can commercialise by the end of this research phase for a domestic and/or international market if the evidence shows improved patient health and well-being outcomes at the same or lower cost to the NHS.REC name
London - Surrey Borders Research Ethics Committee
REC reference
19/LO/0102
Date of REC Opinion
15 Mar 2019
REC opinion
Further Information Favourable Opinion